Responses
Novel treatment (new drug/intervention; established drug/procedure in new situation)
Case report
Glecaprevir/pibrentasvir+sofosbuvir: an optimal retreatment strategy in the setting of HCV NS5A resistance
Compose a Response to This Article
Other responses
No responses have been published for this article.